First Dengue Vaccine Phase 3 Clinical Trial Kicks off at KIMS - Odisha Diary
The third phase of India's first indigenous dengue vaccine, 'DengiAll', has started at Kalinga Institute of Medical Sciences (KIMS). This trial aims to evaluate the efficacy of the tetravalent dengue vaccine developed by Panacea Biotec in collaboration with the Indian Council of Medical Research (ICMR). KIMS is the only hospital in Odisha selected for the Phase 3 trial, which involves 18 other sites across India. The trial commenced with the involvement of key personnel from KIMS and Panacea Biotec, aiming to recruit over 500 participants in Bhubaneswar.
Highlighted Terms
Related News
The third phase of India's first indigenous dengue vaccine, 'DengiAll', has started at Kalinga Institute of Medical Sciences (KIMS). This trial aims to evaluate the efficacy of the tetravalent dengue vaccine developed by Panacea Biotec in collaboration with the Indian Council of Medical Research (ICMR). KIMS is the only hospital in Odisha selected for the Phase 3 trial, which involves 18 other sites across India. The trial commenced with the involvement of key personnel from KIMS and Panacea Biotec, aiming to recruit over 500 participants in Bhubaneswar.
The Phase 3 clinical trial for India's first indigenous dengue vaccine, 'DengiAll', initiated at Kalinga Institute of Medical Sciences (KIMS). The trial aims to assess the efficacy of the tetravalent dengue vaccine developed by Panacea Biotec in collaboration with ICMR. KIMS is the sole hospital in Odisha selected for this trial, which involves 18 other sites across India. The vaccine, originally developed by NIH, USA, has shown promising results in previous trials. The trial commenced with the involvement of key personnel from KIMS and external oversight from ICMR and Panacea Biotec. The global incidence of dengue is increasing, with India and Odisha among the affected regions.